Remove Compounding Remove Dosage Remove Drug Development
article thumbnail

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

Biopharmaceutics is a scientific discipline that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption ( Applied Biopharmaceutics and Pharmacokinetics, Shargel, Wu-Pong and Yu, 5th Edition ).

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biopharmaceutical bioseparation systems market to value $20bn

European Pharmaceutical Review

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 Advancements are underway in terms of product developments and innovations, with significant emphasis being placed on optimising and streamlining existing methods.

Dosage 111
article thumbnail

Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing

Pharmaceutical Technology

With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage? Key considerations in the candidate selection stage The first step in a drug development program is choosing the optimum molecule from a range of potential leads that have been optimized within drug discovery.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.

article thumbnail

Patient Engagement in Pharma – Why and How?

Viseven

The traditional model of drug development and healthcare delivery is undergoing a seismic shift, with patient engagement emerging as a critical factor in achieving better health outcomes and driving innovation. This change is further driven by major regulatory bodies emphasizing Patient-Focused Drug Development (PFDD).

article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Dosage 59